Mirae Asset Global Investments’s Cartesian Therapeutics RNAC Stock Holding History

Mirae Asset Global Investments’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,715	Closed	-$22.8K	–	1734
2026 Q1	$22.8K	Buy	+3,715	New	+$26.5K	﹤0.01%	1414
2025 Q4	–	Sell	-1,005	Closed	-$10.3K	–	1729
2025 Q3	$10.3K	Sell	1,005 -3,713	-79%	-$41.7K	﹤0.01%	1574
2025 Q2	$11.1K	Buy	4,718 +127	+3%	+$1.35K	﹤0.01%	1475
2025 Q1	$13.4K	Buy	4,591 +29	+0.6%	+$518	﹤0.01%	1437
2024 Q4	$17.4K	Buy	4,562 +847	+23%	+$17.1K	﹤0.01%	1438
2024 Q3	$669	Hold	3,715	–	–	﹤0.01%	1545
2024 Q2	$669	Buy	+3,715	New	+$88.7K	﹤0.01%	1519

Other funds holding RNAC

Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return

TFCP

Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

NSIM

North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Mirae Asset Global Investments's RNAC Position: Q2 2026 in Review

Mirae Asset Global Investments sold out of Cartesian Therapeutics (RNAC) in Q2 2026, closing a stake of 3,715 shares — an estimated $22.8K sold.

Mirae Asset Global Investments first reported a position in RNAC in Q2 2024 and held it in 7 quarters. The position peaked at $22.8K in Q1 2026. 17 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Mirae Asset Global Investments reported no remaining Cartesian Therapeutics position as of Q2 2026 after selling out during the quarter.
Mirae Asset Global Investments sold 3,715 Cartesian Therapeutics shares in Q2 2026, an estimated $22.8K.
Mirae Asset Global Investments first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 7 quarters.
Mirae Asset Global Investments's Cartesian Therapeutics position peaked at $22.8K in Q1 2026.
17 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.